Price
Target price
-
-
-
-
-
-
WKN: A3EEV3 / Symbol: HEPA / Name: Hepion Pharmaceuticals / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Hepion Pharmaceuticals Inc. Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Hepion Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Hepion Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hepion Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | -2.180% | -8.082% | -17.622% | 36.376% | 5.467% | -17.061% | - |
| Salarius Pharmaceuticals Inc. | 1.850% | 7.843% | -16.981% | -69.863% | -20.721% | -98.138% | -99.994% |
| Evolus Inc | -1.830% | -4.386% | -15.504% | 39.744% | 16.578% | 23.164% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-29
Initial Reflections on Hepion Pharma's Financials
Upon an immediate observation of the financial statements, several aspects of Hepion Pharma’s fiscal health become apparent. In particular, it’s noticeable that the Biotechnology & Medical Research company has undergone significant financial shifts over the last three years.
Intensive research and development expenditures, consistent net losses, and notable changes in their cash flow are all key features to consider when assessing the company’s financial position.
